News
Vietnam Investment Review on MSN19h
IBI363 earns second breakthrough therapy status for lung cancer in ChinaIBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the ...
News-Medical.Net on MSN1d
SWOG S2302 Pragmatica-Lung study demonstrates value of streamlined clinical trials in real world settingsThe SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...
A grandad with advanced lung cancer which often leaves patients dead within four months has become free of the disease after ...
The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...
MedPage Today on MSN2d
Pre-Op Osimertinib in Lung Cancer Leads to More Major Pathologic ResponsesCHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...
Jeff Cook, 76, was diagnosed with stage four cancer in 2019 and was told that he needed radiotherapy to target the tumour ...
The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...
<li /> 46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with ...
In the Phase III IMforte trial, Tecentriq (atezolizumab) and Zepzelca (lurbinectedin) reduced the risk of disease progression ...
US FDA accepts Roche’s sBLA and grants priority review status for Tecentriq to treat NSCLC: Basel Wednesday, August 4, 2021, 12:00 Hrs [IST] Roche announced that the US Food and ...
Lung cancer is the leading cause of cancer death in Western Australia, and is also the most common and one of the least ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback